CS1003, a novel human and mouse cross-reactive PD-1 monoclonal antibody for cancer therapy.

ABSTRACT: The programmed cell death protein 1 (PD-1) is an immune-checkpoint that negatively regulates the immune system and a key mechanism that tumors utilize to escape from immune surveillance. PD-1 antibodies can block the interaction of PD-1 with its ligands (PD-L1 and PD-L2), restore T cells activation, and elicit antitumor activity. In this paper, we reported a novel PD-1 monoclonal antibody (mAb) CS1003, which is a humanized IgG4 PD-1 mAb generated by conventional hybridoma technology, and currently being developed in multiple clinical trials as monotherapy or in combination with other anticancer agents. We showed that CS1003 bound to recombinant human, cynomolgus monkey, and mouse PD-1 with EC₅₀ values of 0.1757, 0.2459, and 0.3664 nM, respectively. CS1003 blocked PD-1 interactio

SUBMITTER: Li F 

PROVIDER: S-EPMC7921591 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature